Chimerix Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
4,370.00
4,040.00
10,762.00
5,702.00
4,494.00
7,216
SG&A Expense
32,731.00
62,023.00
128,356.00
82,591.00
75,505.00
77,961
EBIT
28,619.00
58,266.00
118,251.00
77,952.00
72,102.00
71,605
Unusual Expense
6,590.00
600.00
-
-
1,160.00
348
Non Operating Income/Expense
4.00
1.00
-
-
-
-
Interest Expense
1,232.00
445.00
-
-
-
-
Pretax Income
36,445.00
59,312.00
117,372.00
76,390.00
70,984.00
69,474
Consolidated Net Income
70,553.00
59,312.00
117,372.00
76,390.00
70,984.00
69,474
Net Income
70,553.00
59,312.00
117,372.00
76,390.00
70,984.00
69,474
Net Income After Extraordinaries
70,553.00
59,312.00
117,372.00
76,390.00
70,984.00
69,474
Net Income Available to Common
70,553.00
59,312.00
117,372.00
76,390.00
70,984.00
69,474
EPS (Basic)
3.65
1.80
2.67
1.65
1.51
1.43
Basic Shares Outstanding
19,307.40
33,003.70
43,878.30
46,267.10
46,963.40
48,593.40
EPS (Diluted)
3.65
1.80
2.67
1.65
1.51
1.43
Diluted Shares Outstanding
19,307.40
33,003.70
43,878.30
46,267.10
46,963.40
48,593.40
EBITDA
28,361.00
57,983.00
117,594.00
76,889.00
71,011.00
70,745
Non-Operating Interest Income
-
-
879.00
1,562.00
2,278.00
2,479
Other After Tax Income (Expense)
34,108.00
-
-
-
-
-

About Chimerix

View Profile
Address
2505 Meridian Parkway
Durham North Carolina 27713
United States
Employees -
Website http://www.chimerix.com
Updated 07/08/2019
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R.